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Abstract
We examined the effects of platelet activators and inhibitors of platelet function on the voltage-gated delayed rectifier
Kq current of human megakaryocytes. We found that both the activators such as thrombin, the thrombin receptor peptide
 42 – 47.TRP and ADP and the inhibitors such as prostacyclin suppressed the delayed rectifier current through two different
 .mechanisms. The cAMP dependent protein kinase A-kinase inhibitor IP blocked the suppression of the delayed rectifier20
current by prostacyclin and failed to block the suppression by thrombin, TRP42 – 47 and ADP. The effects of IP suggest that20
the action of prostacyclin is mediated by A-kinase and the action of the three activators is not mediated by A-kinase.
 .  .Pertussis toxin PTX an inhibitor of the inhibitory GTP-binding proteins G blocked the suppression of the delayedi
rectifier current by thrombin, TRP42 – 47 and ADP and failed to block the suppression by prostacyclin. The effects of PTX
suggests that the action of the three activators is mediated by G or some other PTX-sensitive GTP-binding protein. Wei
speculate that thrombin and other platelet activators that activate G may be suppressing the delayed rectifier current via ai
direct interaction of G or a subunit of it with the delayed rectifier potassium channel itself.i
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1. Introduction
Voltage-gated Kq channels are important for the
function, proliferation and differentiation of blood
w xcells 1–6 . In platelets and megakaryocytes it has
been proposed that voltage-gated Kq channels stabi-
w xlize the resting membrane potential 7–9 .
Voltage-gated channels in non excitable cells can
w x w xbe modulated by mitogens 10,11 , hormones 12 ,
w xG-proteins 13–15 and intracellular second messen-
w xgers 16–18 .
Megakaryocytes are the progenitors of platelets
and as such, share many common features e.g. recep-
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tors and glycoproteins, found in platelets. Thus,
platelet activators and platelet inhibitors are potential
modulators of megakaryocyte function. We used
thrombin and other platelet activators to investigate
whether they modulate the voltage-gated channels of
megakaryocytes. We have found that thrombin and
other platelet activators suppress the voltage-gated
Kq current of human megakaryocytes in a concentra-
tion-dependent manner and also that the suppression
is most likely mediated through a mechanism involv-
ing activation of the inhibitory GTP-binding protein,
G or another PTX-sensitive G-protein.i
We also investigated the effects of prostacyclin, an
inhibitor of platelet function, on the voltage-gated
Kq current of human megakaryocytes. We have found
0167-4889r97r$17.00 Copyright q 1997 Elsevier Science B.V. All rights reserved.
 .PII S0167-4889 96 00145-0
( )L. Kapural, A. FeinrBiochimica et Biophysica Acta 1355 1997 331–342332
that prostacyclin suppresses the current and that the
suppression appears to be mediated by phosphoryla-
tion by A-kinase of the voltage-gated Kq channel
itself or another molecule that then interacts with the
channel.
2. Materials and methods
Bone marrow was obtained from patients for rou-
tine diagnostic and therapeutic purposes. None of
these clinical procedures were performed for our
research experiments. We received the remainder of
the sample after all laboratory procedures were com-
plete.
Megakaryocytes were also collected from bone
marrow filters employed during bone marrow harvest
for marrow transplantation. Bone marrow from
healthy donors was harvested using standard proce-
dure Baxter Fenwal Bone Marrow Collection Kit
.with flexible pre-filter a 4R2107 and passed through
bone marrow filters. The filters, which are normally
discarded, were rinsed with 5 ml of external solution
 .see below . The eluted cells were collected in 10 ml
sterile tubes.
The data in this paper were obtained from 245
human megakaryocytes. Of these cells 152 were ob-
tained from bone marrow filters of 17 healthy donors.
The remaining megakaryocytes were obtained from
bone marrow aspirates from 16 patients with normal
bone marrow. We observed no significant difference
in the data obtained from megakaryocytes that came
from filters or aspirates in the course of this study.
Also in our previous study where we first character-
ized the voltage-gated Kq current of human
megakaryocytes we observed no difference in the
w xdata obtained from filters or aspirates 9 . The above
use of human specimens was approved by the institu-
tional review board.
2.1. Recording chamber
For recording from megakaryocytes 1 ml of di-
luted aspirate was placed in the chamber and left at
room temperature for 30 min to allow the cells to
settle to the bottom of the chamber, which sits on an
 .inverted microscope Nikon Diaphot TMD .
Megakaryocytes were identified for recording on the
basis of their large diameter, )30 mm which al-
lowed them to be clearly distinguished from other
w xbone marrow cells 19 .
2.2. Solutions
The standard external solution that bathed the cells
was composed of 140 mM NaCl, 5 mM KCl, 2 mM
CaCl , 1 mM MgCl , 10 mM HEPES and 10 mM2 2
glucose, adjusted to pH 7.4 with 1 M NaOH. The
internal intrapipette solution was composed of 140
mM KCl and 10 mM HEPES and the pH was
adjusted to 7.35 with 1 M KOH. To buffer changes in
intracellular calcium 15 mM BAPTA was added to
the intrapipette solution.
 .Thrombin 2980 NIH unitsrmg protein , prostacy-
clin, IBMX, 1,9 dideoxyforskolin, ADP, U46619 and
 .IP were from Sigma St Louis, MO and the throm-20
 42 – 47bin receptor peptide TRP or H-Ser-Phe-Leu-
.  .Leu-Arg-Asn-OH was from Bachem Switzerland .
 .Pertussis toxin A protomer PTX and forskolin were
 .from Calbiochem LaJolla, CA . Okadaic acid was
 .from LC Laboratories Woburn, MA . These agents
were applied to the cell at the appropriate concentra-
tions in external solution using either a puffer pipette
or a local superfusion system, the output of which
was placed in close proximity to the recorded cell.
The puffer pipette consisted of a glass pipette with
a tip diameter of 15–30 mm which was connected to
a nitrogen cylinder via a pressure regulator maximal
2.output pressure 2 kgrcm and a solenoid valve. The
regulator was adjusted to obtain rapid flow of solu-
tion out of the pipette without displacing the cell
being recorded from.
The local superfusion system obtained part way
through this study was the DAD-6 Superfusion Sys-
 .tem Adams & List Asoc., LTD, New York . This
system has the ability to rapidly apply agents to
individual cells from 6 reservoirs connected to a
 .micro-manifold. The 100 mm inside diameter out-
put tube of the micro-manifold can be placed in close
proximity to the cell.
When using the puffer pipette or the local superfu-
sion system to apply agents to the cell the bath was
superfused with external solution at a rate of 2
mlrmin. There was no difference in the experimental
findings obtained using the puffer pipette or the local
superfusion system. IP and PTX were applied20
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through the patch pipette by addition to the internal
intrapipette solution.
2.3. Electrophysiological methods
Membrane currents were measured at room tem-
 .perature 21–248C using the whole-cell patch-clamp
w xtechnique 20 and an Axopatch-1D patch-clamp am-
 .plifier Axon Instruments, Foster City, CA . Data
were acquired and analyzed by a computer 486 AT
. clone running PClamp software Axon Instruments,
.Foster City, CA . Recording pipettes were pulled
from 1.5 mm borosilicate glass 7052, Garner Glass
.Inc., Claremont, CA using a two stage Narishige
PB-7 vertical puller and then firepolished on a Nar-
ishige MF-9 microforge. Pipette resistances were be-
tween 3 and 10 MOhms. The Bessel low-pass output
filter of the Axopatch amplifier was set at 1 kHZ and
series resistance compensation was used to minimize
transients. Data analysis was performed using the
PClamp programs Clampex and Clampfit Axon In-
. struments and Sigma Plot for Windows Jandel Sci-
.entific, San Rafael, CA . The sampling rate of 1000
Hz and the low pass filter setting of 1 kHz were fast
enough to analyze the activation kinetics. Activation
and inactivation kinetics were analyzed by fitting first
order time constants to the rising and falling phases
w xof the currents as previously described 9 .
Voltage-gated membrane currents were measured
from a holding potential of y60 mV to be compara-
ble to our previous measurements in human
w xmegakaryocytes 9 .
3. Results
The voltage activated Kq channels of the human
megakaryocytes are the dominant if not the only
w xvoltage activated channels in these cells 9 . In its
voltage dependent activation, inactivation and phar-
macology the voltage-gated Kq channels of human
megakaryocytes are similar to the delayed rectifier
type of Kq channels described in a variety of other
w xcell types 1,7,10 . Therefore, these channels are a
likely target for regulation by agents that affect
 .platelet function see Introduction . Accordingly, we
began this study by exploring the possibility that
these channels are regulated by thrombin.
3.1. Effects of thrombin on the ˝oltage-acti˝ated
potassium current
We examined the effects of thrombin on the volt-
age activated potassium current by puffing thrombin
onto the cell from a nearby puffer pipette see Sec-
.tion 2 . The effect of thrombin was measured repeat-
edly, starting at 1 min and until 5 min of application
when suppression was maximal. To rule out the
possibility that the observed effect was the result of
puffing any solution onto the cell we simply puffed
extracellular solution onto the megakaryocyte using
the maximal pressure that could be applied to the
 .puffer pipette see Fig. 1A and controls in Fig. 3 . A
small portion of the decline in these controls is
simply the result of whole cell recording from the
cells for longer than 10 min. As can be seen in Fig.
1B, thrombin at 0.01 Urml partially suppressed both
the peak and the steady component of the voltage
activated Kq current. The effect of thrombin was
found to be irreversible after 5 min of application,
even after washing for 10 min with extracellular
solution the voltage activated current remained sup-
pressed.
Thrombin acts on its receptor by proteolytically
cleaving the receptor to unmask a new N-terminal
region which then acts as a tethered ligand that binds
 w x.to the receptor see review by Tapparelli et al. 21 .
 42 – 47.A synthetic thrombin receptor peptide TRP
representing the first six amino acids of this N-termi-
nal region, can substitute for thrombin in receptor
w xactivation 22 . To be certain that suppression of the
voltage activated current by thrombin involved acti-
vation of the thrombin receptor, and was not some
non-specific effect of its protease activity, we exam-
ined the effects of TRP42 – 47 on megakaryocytes. Fig.
1C shows the suppression of the megakaryocyte volt-
age activated membrane current by TRP42 – 47. The
findings in Fig. 1 indicate that the first step in the
suppression of the voltage activated outward current
is activation of the thrombin receptor.
It has been proposed that in resting T lymphocytes
w 2qx qan increase in Ca inhibits the voltage-gated Ki
w xcurrent 16,18 . Therefore, we examined whether an
w 2qxincrease in Ca was responsible for the suppres-i
sion of the current in Fig. 1. We repeated the experi-
ment with TRP42 – 47 with 15 mM BAPTA in the
w 2qxintrapipette solution to buffer Ca changes. Thisi
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concentration of BAPTA is sufficient to block activa-
w 2qxtor induced increases in Ca in rat megakary-i
w xocytes 23 . As can be seen in Fig. 2, increasing the
intracellular buffering capacity for calcium failed to
block suppression of the current by 100 mM
TRP42 – 47, indicating that suppression of the current
w 2qxis not the result of a rise in Ca .i
Exposure of megakaryocytes to platelet activators
induces an oscillation of intracellular free calcium
which in turn produces an oscillating calcium acti-
 .Fig. 1. Voltage activated membrane currents I recorded from human megakaryocytes before and after application of thrombin andm
TRP42 – 47. In A–C the first set of traces represent controls obtained before puffing solution onto the cell, the second set of traces were
obtained after the solution was puffed onto the cell, and the graphs give the peak current voltage relationship for the two sets of traces. A.
Control experiment where extracellular solution was puffed onto the cell. B and C effects of thrombin and TRP42 – 47, respectively. In A
we applied the maximum pressure 2 kgrcm2 for 5 min to the puffer pipette. In order to elicit the voltage activated membrane currents the
cells were held at y60 mV and the membrane potential was stepped from y120 mV to 80 mV in 20 mV steps for a period of 1.6 s.
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w xvated potassium conductance 19,24 . Measurement
of voltage activated membrane currents in the pres-
ence of thrombin and TRP42 – 47 were complicated by
this oscillating calcium activated potassium conduc-
tance. These oscillations were present for thrombin
concentrations greater than 0.1 Urml. However, the
maximum amplitude of the oscillations diminished
 .greatly typically decaying to less than 100 pA
 .during prolonged exposure )60 s to the activator.
Because the steady state current is smaller than the
 .peak current see Fig. 1 the oscillation has a greater
effect on measurements of the steady-state compo-
nent. To minimize the effect of the oscillation on the
measurements in Fig. 3, current amplitudes were
measured 5 min after thrombin application started.
In Fig. 3 we examine the concentration depen-
dence for suppression of the peak of the voltage-gated
outward current of megakaryocytes by thrombin and
TRP42 – 47. Where the peak current is defined as the
maximum value of the outward current measured
Fig. 2. Suppression of voltage-gated currents by 100 mM TRP42 – 47 when 15 mM BAPTA was added to the standard intrapipette solution
 .see Section 2 . A. Voltage-gated currents measured immediately upon establishing whole-cell recording. B. Voltage-gated currents
 .recorded more than 20 min after the recordings in A , at a time when dialysis of the cytoplasm with BAPTA had already taken place. C.
Suppression of the voltage-gated currents by 100 mM TRP42 – 47 in the presence of intracellular BAPTA. D. Peak current voltage
 .  .  .relationship for the data in A , B and C . Similar results were obtained in 5 other cells. The voltage protocol was as in Fig. 1.
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after the capacitive transient has subsided. The peak
current was suppressed 50% at a thrombin concentra-
tion of 0.25 Urml. In 20 cells exposed to thrombin in
the concentration range between 0.01 and 1 Urml
there was a maintained change of the holding current,
in the inward direction, of 9.0"1.8 pA.
Having established that activation of the thrombin
receptor leads to a suppression of the voltage acti-
vated outward membrane current in human
megakaryocytes, we next sought to identify the
downstream mechanism by which the suppression
occurs. Two of the primary actions of thrombin are to
stimulate phospholipase C and inhibit adenylate cy-
 w x.clase see review by Brass 25 . In order to deter-
mine if activation of one or both of these second
messenger pathways might be involved in the sup-
pression of the voltage activated outward current we
examined the effects of other platelet activators. The
findings in Fig. 2 can not be taken to imply that
activation of phospholipase C is not involved in
suppression of the current, but only that a rise in
w 2qxCa is not involved in suppression of the current.i
First we examined the effects of ADP which stim-
ulates phospholipase C and inhibits adenylate cyclase
 w x.see review by Siess 26 . As shown in Fig. 4A,
ADP suppressed the voltage-gated outward current as
does thrombin. To eliminate activation of phospholi-
pase C from involvement in suppression of the volt-
age activated outward current we examined the ef-
fects of U46619, a thromboxane A analog. TXA2 2
activates phospholipase C but is not known to stimu-
w xlate or inhibit adenylate cyclase 27 . As can be seen
in Fig. 4A, U46619 did not suppress the voltage-gated
outward current in human megakaryocytes. U46619
caused an oscillating calcium activated potassium
conductance in human megakaryocytes data not
.shown which is consistent with its activating the
w xphospholipase C inositol phosphate cascade 19,24 .
Based on the finding in Fig. 4A with U46619 we
suggest that activation of phospholipase C is proba-
bly not involved in the suppression of the voltage
activated outward current by thrombin.
We also considered the possibility that protein
 .kinase C PKC might somehow be involved al-
though phospholipase C does not appear to be in-
volved. In rat megakaryocytes the PKC inhibitor
staurosporine inhibits calcium activated potassium
w xconductance oscillations 24 . In 4 cells incubated in
400 nM staurosporine for 20 to 30 min a subsequent
exposure to thrombin at 1 Urml suppressed the
voltage-gated outward current by 58"14%, while
failing to produce a calcium activated potassium con-
 .ductance oscillation data not shown . This finding
suggests that activation of PKC is probably not in-
volved in the suppression of the voltage activated
outward current by thrombin.
A common feature of the actions of thrombin and
ADP on platelets is the inhibition of adenylate cy-
clase through receptors which are coupled to adeny-
late cyclase via an inhibitory GTP-binding protein
Fig. 3. A and B: Concentration dependence for suppression of the outward peak current by thrombin and TRP42 – 47, respectively. Peak
current amplitudes were measured for a voltage step to q60 mV. Data in A and B were fit by the smooth curve using the Hill equation
w  .nxy1 42 – 47  .IrI s 1q CrK where C is the concentration of thrombin and TRP respectively and n is the Hill coefficient. In Amax I
 .ns0.33 and K s0.25 Urml, in B ns0.45 and K s13.8 mM. See description of Fig. 1 for further details of how these experimentsI I
were performed.
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 .  w x.G see review by Ashby et al. 28 . By analogy wei
suggest that they inhibit the current by activating Gi
which in turn inhibits adenylate cyclase. However it
is possible that activated G might inhibit the currenti
by a mechanism not involving adenylate cyclase.
Because of the possible involvement of adenylate
cyclase discussed above we also examined the effects
of agents which stimulate platelet adenylate cyclase.
To our surprise these agents also partially suppressed
the current. As shown in Fig. 4B, prostacyclin, which
among other things, is known to activate platelet
adenylate cyclase for review see Aktories & Jakobs
w x. q29 suppressed the voltage-gated K current. To
investigate whether the effect prostacyclin was in-
deed the result of activation of adenylate cyclase we
used forskolin which bypasses the receptor and di-
w xrectly activates adenylate cyclase 30 . At a concen-
tration of 100 mM, forskolin also suppressed the
q  .voltage activated outward K current Fig. 4B .
Likewise, the phosphodiesterase inhibitor 3-isobutyl-
 .1-methylxanthine IBMX which should elevate
w xcAMP levels by inhibiting cAMP degradation 31 ,
 .suppressed the current as well see Fig. 4B . The
voltage-gated outward current decreases in amplitude
during the first 5 min of recording in normal extracel-
lular solution, after that period the amplitude stabi-
lizes with an average loss of about 10% of the current
Fig. 4. Effect of different agents on the peak amplitude of the
voltage- gated outward Kq current. The mean and standard
deviation of the normalized peak current amplitude for a voltage
step to q60 mV is given as the amplitude measured after the
agent was applied to the cell for 3 min divided by the amplitude
of the control measured just before application of the agent. A.
Suppression of the voltage-gated outward current by ADP 40
. 42 – 47  . mM, ns5 , TRP 100 mM, ns5 , thrombin 1 Urml,
.  .ns4 and U 46619 I mM, ns5 . The controls were obtained
).by puffing extracellular solution onto the cells. An asterix is
used to indicate normalized peak amplitudes which are not
significantly different than control at the P s0.05 level. All
other means of the peak current were significantly different than
control at P s0.05 level using the unpaired Student’s t-test. B.
Effect of agents which raise platelet cAMP on the peak amplitude
of the voltage-gated outward current in megakaryocytes. Mean
and S.D.s of peak amplitudes were measured for a voltage step to
q60 mV before and after application of prostacyclin 2.8 mM,
.  .  .ns5 , IBMX 20 mM, ns5 and forskolin 100 mM, ns5 as
described above. Means of the peak currents for all three agents
were significantly different than control at the P s0.05 level
using the unpaired Student’s t-test.
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amplitude see control measurements in Fig. 1 and
.Fig. 3 . Therefore, we tested to see if the difference
of the means of peak current amplitudes when
forskolin, IBMX and prostacyclin were used were
statistically different compared to control. Using the
unpaired Student’s t-test we found the difference to
be significant at the 0.05 level. The suppression of
the current by IBMX, prostacyclin and forskolin sug-
gest that activation of adenylate cyclase and the
resulting rise in cAMP suppresses the voltage-gated
outward Kq current.
In Fig. 1 it appears that thrombin and TRP42 – 47
caused the activation kinetics of the outward current
to decrease. Therefore we examined the effects of
several platelet activators and inhibitors on the activa-
tion and inactivation kinetics of the voltage-gated
outward current. Changes in activation and inactiva-
tion kinetics of the voltage-gated Kq current by
 .  . 42 – 47  .thrombin ns4 , ADP ns5 , TRP ns5 ,
 .  .PGI ns5 , and IBMX ns5 are measured as the2
difference between the time constant measured after
application of the agent and that measured before.
Both the rise time and fall time of the voltage-gated
outward current are well fit by a single exponential
and control values for activation and inactivation
w xhave been published previously 9 . There was no
systematic effect of the two groups of agents on
either the activation or inactivation kinetics see Sec-
.tion 2 except for a somewhat generalized slowing of
 .the kinetics data not shown .
The effects of the two groups of agents are rather
small and we wanted to rule out the possibility that
the effects were the result of some subtle type of
artifact. We thought we could realistically rule out an
artifact if we could pharmacologically block the ef-
fects of both groups of agents by blocking known
biochemical pathways. We also wanted to answer the
question of how it could be that both, activators and
inhibitors of adenylate cyclase suppress the voltage-
gated outward current. One possible explanation is
that one group of agents might not in fact be working
via adenylate cyclase. In many instances the effects
of cAMP are thought to be mediated by a cAMP-de-
Fig. 5. Effects of different agents on the peak amplitude of
voltage-gated Kq outward current for a voltage step to q60 mV
in the presence and absence of IP an inhibitor of cAMP20
dependent protein kinase. We added IP to the standard internal20
solution in the recording pipette at a concentration of 50 mM. A.
Effect of prostacyclin, IBMX and forskolin in the presence and
absence of IP . B. Effect of thrombin, TRP42 – 47 and ADP in the20
 .presence and absence of IP . IBMX 20 mM, ns5 , prostacy-20
 .  .clin 2.8 mM, ns6 and forskolin 100 mM, ns5 were
 .applied using the local superfusion system see Section 2 .
 . 42 – 47  .Thrombin IUrml, ns4 , TRP 100 mM, ns4 and ADP
 .40 mM, ns5 were applied similarly. Controls with IP pre-20
 .sent in the patch pipette ns34 were obtained as follows.
Immediately upon obtaining whole cell recording the peak out-
ward current for a q60 mV voltage step was measured. We then
waited 20 min to allow the IP to diffuse into the cell and reach20
its site of action. During this time the peak outward current for a
voltage step to q60 mV was measured several times. Controls
are given as the ratio of the peak outward current measured at 20
min to that measured upon attaining whole cell recording. Fol-
lowing measurement of controls the different agents were applied
to the cell.
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 . pendent protein kinase A kinase see review by
w x.Siess, 1989 26 . Therefore we tested the ability of
both groups of agents to suppress the current in the
 .presence of IP , an inhibitor of A-kinase Fig. 520
w x32 . IP which was applied through the patch pipette20
 .see Section 2 blocked the suppression of the current
by prostacyclin and IBMX while forskolin sup-
pressed the current significantly even in the presence
 .of IP . see Fig. 5A . The finding that suppression of20
the current by prostacyclin and IBMX is blocked by
IP suggests that these agents act by elevating cAMP20
levels, thereby activating A-kinase. On the other hand
IP fails to block the suppression of the current by20
42 – 47  .thrombin, TRP and ADP see Fig. 5B suggest-
ing that these three agents are not acting via A-kinase.
The inability of IP to block the effect of forskolin20
might be explained by a direct effect of forskolin on
q w xthe voltage-gated K channels 33 . Therefore we
examined the effects of the forskolin analog 1,9-dide-
w xoxyforskolin which does not raise cAMP 34 . We
found that both forskolin and 1,9-dideoxyforskolin
suppress the current with a similar potency. The K i
 .see caption of Fig. 3 for suppression of the current
 .by either was 34.8 mM data not shown . These
findings indicate that suppression of the voltage-gated
current by forskolin is not related to forskolin’s abil-
ity to raise cAMP.
If the suppression of the voltage-gated current by
prostacyclin is mediated by phosphorylation of the
underlying ion channel by A-kinase, then the cell
should posses a protein phosphatase which dephos-
phorylates the channel. Therefore we also tested PGI2
mediated suppression of the voltage-gated current
when cells were preincubated with 1 mM okadaic
w xacid, a protein phosphatase inhibitor 35 . Okadaic
acid significantly potentiated PGI mediated suppres-2
sion of the voltage-gated current. PGI suppressed2
 .the current by 66"12% ns6 cells, data not shown
in the presence of okadaic acid while it only sup-
pressed the current 30"7% when applied alone Fig.
.4B .
Given that thrombin, TRP42 – 47 and ADP are not
suppressing the voltage-gated outward current via
A-kinase, we thought it was important to establish
that they were in fact working via G as we assumed.i
 .To this end we used pertussis toxin PTX to inhibit
w xG 36 . As expected, addition of pertussis toxin Ai
protomer to the intracellular solution see Section 2
Fig. 6. Effects of different agents on the amplitude of the peak of
voltage-gated Kq current for a voltage step to q60 mV in the
presence and the absence of pertussis toxin A protomer. Pertussis
toxin A protomer was added to standard internal solution in the
patch pipette at a concentration of 50 nM. A. Pertussis toxin
blocked the suppression of the current by thrombin IUrml,
. 42 – 47  .  .ns5 , TRP 100 mM, ns5 and ADP 40 mM, ns5 . B.
 .Suppression of the current by prostacyclin 2.8 mM, ns5 ,
 .  .IBMX 20 mM, ns5 and forskolin 100 mM, ns4 was not
 .blocked by pertussis toxin. Controls with PTX ns33 in the
patch pipette were obtained using the same procedure as de-
scribed for IP in the caption to Fig. 5. After whole cell20
recording was established and the cell was left for at least 20 min
to obtain controls with pertussis toxin the agents were applied
 .using the local superfusion system see Section 2 .
.and caption of Fig. 6 blocked the suppression of the
voltage-gated current by thrombin, TRP42 – 47 and
 .ADP Fig. 6A . As a control for the specificity of
PTX, we tested the ability of prostacyclin, IBMX and
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forskolin to suppress the current in the presence of
PTX. Again, as expected the ability of these agents to
suppress the current was unaffected by PTX. We
therefore conclude that suppression of the current by
thrombin, TRP42 – 47 and ADP is mediated via activa-
tion of G or another pertussis toxin sensitive G-pro-i
tein.
By what mechanism does activation of G suppressi
the voltage-gated current. One possibility is that Gi
activates phospholipase A . Platelet activators cause2
a rapid release of arachnidonic acid, which results in
part from direct hydrolysis of phospholipids by phos-
pholipase A , which might be activated by a GTP-bi-2
w xnding protein such as G 25 . If phospholipase A isi 2
involved, our experiments indicate that the effector is
not TXA , since U46619 did not suppress the current2
 .see Fig. 4 .
Phospholipase A involvement was examined by2
incubating cells with 1 mM of the phospholipase A 2
w xinhibitor 4-bromophenacyl bromide 37 and then
applying ADP at the same concentration as in Fig. 4.
In the presence of bromphenacyl bromide ADP sup-
pressed the current by 38"7% ns5 cells, data not
.shown which is not significantly different than its
 .effect when applied alone Fig. 4 . We conclude that
suppression of the voltage-gated current by platelet
activators, such as ADP, is not mediated by phospho-
lipase A .2
If the activators and inhibitors are suppressing the
voltage-gated Kq current by independent mecha-
nisms, as the findings of Fig. 5 and 6 suggest then
their effects may be additive. To demonstrate this
additivity we applied ADP and PGI together. We2
found that when both were applied together 2.8 mm
.  .PGI and 40 mm ADP 75"5% ns5 cells of the2
 .current was suppressed data not shown . This is not
significantly different from the sum of the suppres-
sion when each were applied alone. The current was
 .suppressed 55"15% ns5 cells by 40 mm ADP
 .and 30"7% ns5 cells by 2.8 mM PGI alone2
 .see Fig. 4 .
4. Discussion
We have found that in human megakaryocytes the
voltage-gated outward Kq current described previ-
w xously 9 , is suppressed, in a concentration-dependent
fashion, by thrombin and the thrombin receptor pep-
tide acting via the thrombin receptor Fig. 1 and Fig.
.3A .
In order to try and elucidate the downstream mech-
anism of the suppression of the voltage-gated out-
ward current by thrombin we examined the effects of
other platelet activators. The thromboxane A analog2
U46619, which activates phospholipase C did not
 .suppress the current see Fig. 4A which argues
against the involvement of phospholipase C activa-
tion in suppression of the current. This is supported
in part by the finding that raising the intracellular
buffering capacity for calcium, to suppress changes in
w 2qxCa , does not block suppression of the current byi
42 – 47  .TRP see Fig. 2 . We also found that stau-
rosporine failed to block suppression of the current
by thrombin which argues against the involvement of
PKC.
Those platelet activators in Fig. 4A which suppress
the current are potent inhibitors of platelet adenylate
cyclase working through receptors coupled to cyclase
via G which suggests that inhibition of adenylatei
cyclase via G is intimately involved in suppressioni
of the current.
However, we found that IP failed to block the20
suppression of the current by thrombin, TRP42 – 47 and
ADP and IP itself, which inhibits A-kinase, does20
 .not suppress the current Fig. 5 , indicating that
inhibition of A-kinase does not lead to suppression of
the current. It may still be possible that these activa-
tors are working via cAMP directly. This possibility
seems unlikely based on the results with prostacyclin
and IBMX: suppression of the current by prostacyclin
 .and IBMX can be blocked by IP Fig. 5A indicat-20
ing that their action is not mediated by a direct affect
of cAMP on the delayed rectifier. Thus, it is unlikely
that cAMP directly affects the voltage-gated outward
current but rather works via A-kinase. Taken together
the findings in Fig. 4 and 5 suggest that suppression
of the voltage-gated outward current by platelet acti-
vators such as thrombin is mediated by G withouti
the involvement of cAMP or A-kinase. Also, the
inability of bromphenacyl bromide to block the sup-
pression of the current by ADP indicates that G isi
not working by activating phospholipase A .2
Our strongest evidence that the platelet activators
are suppressing the current via activation of G , isi
that PTX blocks their ability to suppress the current
( )L. Kapural, A. FeinrBiochimica et Biophysica Acta 1355 1997 331–342 341
 .Fig. 6A . That PTX acts by ADP-ribosylating G ai
and not G a in human megakaryocytes is supportedo
w xby experiments in human platelets 38 where anti-
serum to G a immunoprecipitate two proteins ADP-i
ribosylated by PTX while antiserum to G a fails too
immunoprecipitate such proteins.
As mentioned above, suppression of the current by
 .prostacyclin and IBMX is blocked by IP Fig. 5A20
indicating that elevation of cAMP, by activation of
adenyl cyclase or inhibition of phosphodiesterase,
activates A-kinase which leads to suppression of the
voltage-gated outward current, most probably by
phosphorylation. The suggestion that phosphorylation
of the delayed rectifier leads to suppression of the
 .channel is consistent with the finding see Results
that the protein phosphatase inhibitor okadaic acid
enhances the suppression of the current by prostacy-
clin. Modulation of voltage-gated potassium channels
by A-kinase mediated phosphorylation has been
w xshown to occur in other cell types 39–42 .
On the basis of the above data we propose that
there are two different pathways for suppression of
the delayed rectifier Kq current in human megakary-
ocytes as described schematically in Fig. 7. One
pathway involves platelet activators such as thrombin
which activates its receptor which in turn activates
G , that then either directly or indirectly suppressesi
the delayed rectifier potassium channel. The other
pathway involves agents that suppress platelet func-
tion, such as prostacyclin, which activates cyclase via
its receptor and G thereby raising cAMP concentra-s
tion leading to the activation of cAMP dependent
protein kinase which then suppresses the delayed
rectifier by phosphorylation. For the sake of simplic-
ity in Fig. 7, A-kinase is shown as acting directly on
the channel, although we have no evidence that its
action is direct.
One possibility is that G directly suppresses thei
delayed rectifier. Direct gating of Kq channels by
receptor activated G-proteins has been shown to oc-
w xcur in neurons and heart cells 43,44 . Also in a mast
cell line and murine macrophages G-protein activa-
tors regulate Kq channel function, although it was
not established that this was the result of a direct
interaction between the channel and a G-protein
w x13,14 . We favor the idea of a direct interaction
between G and the delayed rectifier in megakary-i
ocytes, because our findings indicate that effectors
such as phospholipase C, calcium, phospholipase A 2
and adenylate cyclase are not involved in mediating
the interaction.
In platelets, prostacyclin acts to block activation
by agents such as thrombin and ADP for example
w x.see Brass 25 . In contrast, we found that prostacy-
clin and ADP act additively to suppress the current in
megakaryocytes. That a platelet inhibitor and a
Fig. 7. Putative mechanisms for suppression of the delayed rectifier voltage-gated Kq current of human megakaryocytes by thrombin and
prostacyclin. See text for details.
( )L. Kapural, A. FeinrBiochimica et Biophysica Acta 1355 1997 331–342342
platelet activator are apparently working together to
suppress the voltage-gated outward current in
megakaryocytes might be related to the process of
megakaryocyte development or to a function unique
to megakaryocytes and not found in platelets, such as
the production of the platelet itself.
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